Closed · RFA-CA-19-007 · CFDA 93.395 · Discretionary
The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trials Required)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $1.3M
- Award range
- Closed
- Status
- May 22, 2019
- Close date
- -
- Expected awards
The verdict
The Experimental Therapeutics Clinical Trials Network (UM1 Clinical Trials Required) is a closed discretionary listing from National Institutes of Health that offered Up to $1,250,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- up to $1.3M
- award range
- Closed
- application status
- 93.395
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
The Experimental Therapeutics Clinical Trials… is closed (last close May 22, 2019). The parent program page for CFDA 93.395 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed May 22, 2019
Instrument
Cooperative Agreement
Description
The purpose of this Funding Opportunity Announcement (FOA) issued by The National Cancer Institute (NCI) is to continue support for the Experimental Therapeutics Clinical Trials Network (ETCTN) for the efficient and comprehensive conduct of early phase clinical trials of NCI Investigational New Drug (IND) agents. The ETCTN is designed to assure the availability of investigators and programs with expertise in early drug development and translational research for this purpose. This FOA solicits UM1 cooperative agreement applications from appropriate multidisciplinary groups that can assemble an appropriate infrastructure and conduct phase 0, phase 1, phase 2, pilot and other experimental therapeutics clinical trials involving agents for which the NCIs Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP) received IND status. The FOA is open to any qualified applicant regardless of whether they have been previously associated with the ETCTN.
Market-open applicant set · includes for-profit door
The eligibility set for The Experimental Therapeutics Clinical Trials… includes a for-profit door among 8 printed types (State governments; Public / state-controlled institutions of higher education; Nonprofits with 501(c)(3) status (other than IHEs); Nonprofits without 501(c)(3) status (other than IHEs); +4 more). Competitive traffic can include commercial applicants alongside other listed classes. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Education · Health (ED;HL). Only 98 other National Institutes of Health listings share this exact eligibility-code string (1% of 12,420).
- Code 00
- State governments
- Code 06
- Public / state-controlled institutions of higher education
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 13
- Nonprofits without 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 22
- For-profit organizations other than small businesses
- Code 23
- Small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Cancer Treatment Research
National Institutes of Health
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
The Experimental Therapeutics Clinical Trials… is closed; use the parent program and agency catalog for the next funding cycle.
- Parent CFDA 93.395 may publish future NOFOs under the same assistance listing. Open program
- Cancer Treatment Research indexes 60 Grants.gov listings in this extract. Program profile
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |